Cry1Ac from Bacillus thuringiensis ssp. kurstaki HD-73 is a poreforming protein speci®cally toxic to lepidopteran insect larvae. It binds to the cell-surface receptor aminopeptidase N in Manduca sexta midgut via the sugar N-acetyl-d-galactosamine (GalNAc). By using 1,3-diaminopropane (DAP) as the buffer throughout protoxin activation and chromatography on Q-Sepharose at pH 10.3, trypsin-activated Cry1Ac has been puri®ed in a monomeric state, which was crucial to obtaining single crystals of Cry1Ac and of the . Data sets collected to 2.36 and 2.95 A Ê resolution, respectively, show that both crystal forms contain four molecules of the 66 kDa toxin in the asymmetric unit and have related packing arrangements. The deaggregating effect of DAP may be explained by its capacity for bivalent hydrogen bonding and hydrophobic interactions at protein interfaces.
Introduction
The toxicities of -endotoxins produced by B. thuringiensis (Bt) during sporulation are speci®cally directed towards insects of the orders Lepidoptera (moths and butter¯ies), Diptera (mosquitoes and black¯ies) and Coleoptera (beetles) (Ho È fte & Whiteley, 1989; Margalit, 1989) . These toxins recognize receptor proteins on the brush-border membrane surface of the insects' midgut epithelium (Hofmann et al., 1988; van Rie et al., 1989; van Rie, Jansens et al., 1990) . Receptor binding triggers a conformational change in the toxin (Li et al., 1991; Schwartz et al., 1997) , allowing it to insert into the insect membrane and form lytic pores (Knowles & Ellar, 1987) , leading ultimately to insect death (Knowles, 1994) . Thus, receptor binding by -endotoxins not only determines insecticidal selectivity, but can also affect their pore-forming potency (van Rie, McGaughy et al., 1990; Tabashnik et al., 1994) .
Cry1Ac is the only Bt -endotoxin, of at least 73 members of the family (Crickmore et al., 1995) , for which a membrane receptor and the ligand on that receptor responsible for speci®city determination are both known. It is produced by B. thuriengiensis ssp. kurstaki HD-73 as a protoxin of 133 kDa and proteolytically activated to the 66 kDa toxin (Ho È fte & Whiteley, 1989) in the midgut of the susceptible insect. The Cry1Ac receptor in the insect Manduca sexta has been identi®ed as aminopeptidase N (APN), a 120 kDa glycoprotein with a glycosylphosphatidyl-inositol (GPI) anchor in the membrane (Knight et al., 1994; Garczynski & Adang, 1995; Sangadala et al., 1994) . Cry1Ac receptors in several other lepidopteran insects have also been shown to be aminopeptidases N (e.g. Gill et al., 1995; Valaitis et al., 1995) .
N-acetyl-d-galactosamine (GalNAc) is the high-af®nity ligand on M. sexta APN speci®-cally recognized by Cry1Ac. It speci®cally decreased the cytotoxicity of Cry1Ac (Knowles et al., 1984) , inhibited the saturable binding of Cry1Ac to BBMV and blocked Cry1Ac binding to the 120 kDa protein in ligand blots (Knowles et al., 1991) . In surface plasmon resonance (SPR) experiments using immobilized M. sexta APN, GalNAc caused dissociation of bound Cry1Ac with a K i of 5 mM, but not of the closely related Cry1Aa or Cry1Ab which also bind to APN . SPR analysis of Cry1Ac binding to M. sexta APN in a supported lipid monolayer resolved an initial rapid reversible (low-af®nity) phase from a slower irreversible (high-af®nity) phase (Cooper et al., 1998) . Whereas the low-af®nity phase was GalNAc-sensitive, the higher af®-nity phase, which follows ®rst-order kinetics, was sensitive to neither GalNAc nor reagents that disrupt protein±protein interactions. It crystallization papers suggests that the GalNAc-mediated binding to the APN receptor is immediately followed by a rate-limiting step in the mechanism enabling the toxin to insert into the lipid.
The crystal structure of a Cry1Ac± GalNAc complex will identify directly the toxin residues responsible for recognizing the speci®city determinant on insect APN. Comparison of the ligand-bound and free toxin structures can also reveal the immediate structural repercussions of the receptor binding leading to the major conformational change required for pore formation. Clues to speci®city determination may also be extracted through structural comparison of Cry1Ac with the closely related Cry1Aa (Grochulski et al., 1995; PDB code 1ciy) , which shares a 70% sequence identity with Cry1Ac (Crickmore et al., 1995) but unlike Cry1Ac does not bind GalNAc , and comparison with the more remotely related Cry3A (Li et al., 1991; PDB code 1dlc) , which possesses toxicities to coleopteran rather than lepidopteran insects. We describe here the crystallization of Cry1Ac both as a free toxin and in a complex with GalNAc, with emphasis on overcoming non-speci®c protein aggregation. Non-crystallographic symmetry in the two crystal forms is also described.
Methods

Preparation of the Cry1Ac toxin by trypsin cleavage of the protoxin
Parasporal inclusions from B. thuringiensis ssp. kurstaki HD-73 containing 40 mg of the Cry1Ac protoxin were suspended at 5 mg ml À1 in 50 mM 1,3-diaminopropane (DAP, Fluka) pH 9.8 containing 300 mM NaBr (digestion buffer). A stock solution of N-tosyl-l-phenylalanine chloromethyl ketone (TPCK) treated trypsin (Sigma) was brought to 100 mg ml À1 in 0.5 mM sodium citrate pH 3.0; TPCK (Sigma) was dissolved to 100 mM in ethanol. Digestion was initiated by adding 1 mg ml
À1
of TPCK-treated trypsin and 0.1 mM TPCK (®nal concentrations) to the protoxin suspension. The mixture was incubated in a 310 K water bath with gentle agitation for 10 h. The maximum yield of activated toxin was obtained by collecting the supernatant at 2 h intervals by centrifugation in an Eppendorf microcentrifuge. After adding 0.1 mM N-tosyl-l-lysine chloromethyl ketone (TLCK, Sigma) and 0.2 mM phenylmethylsulfonyl¯uoride (PMSF, Sigma) and adjusting the pH to 10.3, the supernatant was immediately subjected to anion-exchange chromatography (see below). The pellet was resuspended in one half of the starting volume in digestion buffer plus 1 mg ml À1 TPCK-treated trypsin for continued digestion.
Anion-exchange chromatography
Pre-packed 5 ml Q-Sepharose anionexchange columns (Pharmacia HiTrap Q) were connected to a Pharmacia FPLC system. Buffer A consists of 34 mM DAP pH 10.3; buffer B consists of 750 mM NaBr in buffer A. The column was equilibrated with 25 ml of 13% buffer B (98 mM NaBr in 34 mM DAP pH 10.3). Supernatant from trypsin digestion was adjusted to pH 10.3 by the addition of 0.5 M DAP at that pH and loaded onto the column. Trypsin present in this sample was removed by washing the column successively with 50 ml of 13% buffer B, 10 ml of a linear gradient of 13± 20% buffer B (98±150 mM NaBr) and 20 ml of 20% buffer B. The column was then developed with two consecutive linear gradients of 20±36% buffer B (150±270 mM NaBr) in 5 ml followed by 36±40% buffer B (270±300 mM NaBr) in 10 ml. Activated Cry1Ac was eluted in a peak of about 8 ml starting at 28% buffer B (210 mM NaBr). Finally, the column was washed with 10 ml of 100% buffer B and re-equilibrated with 5 ml of 13% buffer B for re-use. When the digestion was carried out as successive 2 h incubations, peak fractions containing activated Cry1Ac were pooled from all incubation periods and concentrated by repeating the chromatography procedure as described.
Protein concentration and pre-mixing of Cry1Ac with GalNAc
For crystallization of the free toxin, activated Cry1Ac was concentrated to 3.5 mg ml À1 in 1±2 ml by centrifugal ultra®ltration in Centriprep-30 (Amicon) units spun at 2500 rev min À1 at 277 K. It was then dialysed to the starting condition for crystallization at 277 K overnight against a 50 ml reservoir of 50 mM DAP pH 10.3 containing 300 mM NaBr, 2% 2-methyl-2,5-pentanediol (MPD), 25%(v/v) glycerol, 3 mM NaN 3 and 0.1 mM PMSF. The protein concentration increased slightly owing to the osmotic effect of the glycerol and was readjusted to 3.5 mg ml À1 by addition of dialysis buffer. For cocrystallization with GalNAc, ultra®ltration was interrupted when the protein concentration reached 2.5 mg ml À1 to allow pre-mixing with the ligand. A 50%(w/v) solution of GalNAc was prepared in 30 mM DAP pH 10.3, 300 mM NaBr and 20%(v/v) glycerol and chilled. 80 ml of the GalNAc stock was added in 10 ml aliquots every 5 min to 2 ml of the Cry1Ac, with gentle mixing by pipette between additions. After the last addition, the mixture was incubated for 1 h on ice before resuming ultra®ltration to a ®nal concentration of $3.5 mg ml À1 . The sample was dialysed to the starting condition for crystallization, which was identical to that for crystallization of the free toxin except that GalNAc was included at 1.5%(w/v) and the glycerol concentration was reduced to 20%(v/v). Protein concentration was readjusted to 3.5 mg ml À1 .
Analytical methods
Protein purity was monitored by SDS± PAGE using Coomassie or silver staining. The N-terminal sequence of major bands was determined after electroblotting onto Immobilon paper. For electrospray mass spectrometry, puri®ed Cry1Ac was dialysed into 0.1%(v/v) tri¯uoroacetic acid. Particle- crystallization papers size distribution in solution was determined by dynamic light scattering (D'Arcy, 1994) from Cry1Ac samples at a minimal concentration of 0.5±1.0 mg ml À1 , which had been ®ltered through Milex (MilliPore) syringe ®lters of 0.02 mm pore size. Measurements were taken on a DynaPro-801 instrument and analysed using the Dynamics software supplied by with the instrument. The translational diffusion coef®cient (D T ), apparent mass, mean hydrodynamic radius (R H ) and polydispersity (standard deviation of R H ) ®tted to a unimodal or bimodal model of size distribution. Goodness of ®t was indicated by a baseline close to 1.000 and a sum-ofsquare error below 1.
BBMV-binding assay
Brush-border membrane vesicles (BBMV) were prepared from midguts of ®fth-instar larvae of M. sexta using the Mg 2+ -precipitation method of Wolfersberger et al. (1987) with minor modi®cations (Carroll & Ellar, 1993) . Cry1Ac binding to the BBMV was estimated by the`spin-down' assay according to Knowles et al. (1991) . Brie¯y, BBMV were incubated at 293 K with activated Cry1Ac in phosphate-buffered saline (PBS) containing 1 mg ml À1 BSA (to prevent non-speci®c binding), with or without 2%(w/v) GalNAc or 20%(v/v) glycerol or with both, as indicated. After 30 min, the mixture was centrifuged at 12 000g for 15 min and aliquots of the supernatant and the pellet (twice washed with PBS) were analysed by SDS± PAGE. A blot of the gel on nitrocellulose paper was incubated with 3%(w/v) bovine haemoglobin to block nonspeci®c binding, then immune labelled with Cry1Ac-speci®c antibodies. Bound Cry1Ac antibodies were detected by a reaction using peroxidaseconjugated secondary antibodies.
Crystallization
Cry1Ac was dialysed in 10 ml microdialysis buttons (Repetition Engineers, Cambridge, England) at room temperature against reservoirs of 2 ml volume held in the wells of 24-well Linbro plates, which were sealed with cover slips and vacuum grease as for hanging drops. This arrangement facilitated screening of different dialysis conditions on a grid. After crystals appeared, the buttons were transferred to 15 ml glass vials to continue dialysis against larger reservoirs at 277 K. The vials were sealed with glass cover slips so that crystal growth could be observed without breaking the seal.
X-ray data collection and processing
Crystals were stabilized in two stages in buffers containing cryoprotectant. The stabilizing buffer for Cry1Ac crystals consisted of 50 mM Tris pH 8.5, 10 mM NaBr and 15% glycerol. For cocrystals of Cry1Ac with GalNAc it contained in addition 0.4%(w/v) GalNAc. Crystals were ®rst transferred to a 1:1 mixture of the ®nal crystallization reservoir and a solution of 50% MPD in the stabilizing buffer, incubated for 10 min and then transferred to a solution of 30% MPD in the stabilizing buffer. Crystals were then¯ash frozen either by plunging into liquid N 2 or exposing to the N 2 vapour at 100 K. Diffraction data were collected on MAR image-plate scanners (MAR Research, Hamburg) using a rotating-anode gnerator or synchrotron radiation. Data were processed using MOSFLM, SCALA and other programs from the CCP4 suite (Collaborative Computational Project, Number 4, 1994). Self-rotation functions were calculated using the program GLRF (Tong & Rossmann, 1997) .
Results
Purity of Cry1Ac
Cry1Ac puri®ed by trypsin activation of the protoxin at pH 9.8 followed by anionexchange chromatography on Q-Sepharose at pH 10.3 (Fig. 1a) showed a single band of about 66 kDa apparent molecular weight on SDS±PAGE (Fig. 1b) . N-terminal sequencing indicated the ®rst residue to be Ile29, in agreement with the N-terminal activation site reported for other Cry1A toxins (Convents et al., 1991) . Electrospray mass spectrometry of the protein dissolved in 0.1%(v/v) TFA resolved two components present at an abundance ratio of 100:85 with masses of 65 997 and 66 496 Da, respectively. These values correspond closely to the calculated masses, 65 961.1 and 66 473.7 Da, respectively, for two activation products with a common N-terminus at Ile29 and C-termini at Tyr616 and Arg620. Cleavage after Tyr616 shows that some chymotrypsin activity was present during trypsin cleavage of the protoxin, but no detectable chymotrypsin cleavage occurred between Ile29 and Tyr616.
Aggregation state of purified Cry1Ac
Table 1 presents the results from dynamic light scattering as bimodal size distributions. Monodispersity is normally indicated when >99% of the scattered amplitudes are accounted for by a single size class. Table 1 (a) shows clearly that with DAP as the buffer during both the activation and anion-exchange steps puri®ed Cry1Ac was monodisperse with a deduced molecular weight of the monomer. In contrast, all other buffers suitable for the required pH range resulted in polydisperse and highly aggregated protein, such that at least one third of the scattering amplitudes were from particles larger than 3000 kDa, roughly 50 times the monomer mass. This clearly indicates non-speci®c aggregation. Table 1(b) and Fig. 1 show that when NaBr was used as the eluting salt, the aggregated material was separated from the monomeric component (peak 1 in Table 1b and Fig. 1a ) into a , 20 mM pH 9.8; piperazine, 20 mM pH 9.8. Where necessary, buffer exchange between activation and ion-exchange chromatography was achieved by gel ®ltration on a PD-10 column (Pharmacia). ³ D T , translational diffusion coef®cient. § R H , mean hydrodynamic radius. crystallization papers trailing peak (peak 2), whereas when NaCl or KCl was used instead, it barely formed a shoulder on the monomeric peak (data not shown).
After the column-puri®ed monomeric Cry1Ac was dialysed at a protein concentration of 3.5 mg ml À1 to the starting condition for crystallizations (xx3.4 and 3.5), dynamic light-scattering measurements (Table 1c ) indicated formation of particles roughly the size of a tetramer, which accounted for about 90% of the scattering. These particles appear distinct from the larger polydisperse aggregates (Table 1a) formed in buffers other than DAP and may represent soluble precursors to the noncrystallographically related pair of dimers observed in the crystals (see x3.7).
Effect of glycerol on GalNAc-mediated BBMV binding
Glycerol was required at concentrations around 20%(v/v) in order to change the morphology of Cry1Ac crystals from needles to plates. However, glycerol has been reported to inhibit protein±carbohydrate interaction (Tsitsanou et al., 1999) . Therefore, we checked whether GalNAc-mediated receptor binding by Cry1Ac can be maintained in glycerol by comparing Cry1Ac binding to BBMV in the presence and absence of 20%(v/v) glycerol. Fig. 2 shows SDS±PAGE analysis of the BBMV-binding assays. In the absence of glycerol, Cry1Ac is entirely bound to the BBMV prepared from midguts of the target insect M. sexta, hence it co-sedimented with the vesicles (lanes 8 and 9) . Inclusion of 2% GalNAc in the incubation with BBMV completely abolished the binding (lanes 10 and 11), con®rming that GalNAc is the high-af®nity ligand through which Cry1Ac binds to the membrane receptor in M. sexta (Knowles et al., 1991) . When 20%(v/v) glycerol was present in the incubation with BBMV, all except about 5% (judging from intensity of the peroxidase reaction) of the Cry1Ac still co-sedimented with the BBMV (compare lanes 12 and 13 with lanes 8 and 9). When GalNAc was added together with the glycerol, it again completely abolished Cry1Ac binding to BBMV (lanes 14 and 15). Thus, glycerol interference with GalNAc-mediated receptor binding is insigni®cant and a stable Cry1Ac±GalNAc complex can be observed directly by crystallographic analysis.
Crystallization of Cry1Ac
In preliminary screens the solubility of Cry1Ac was found to increase with pH, ionic strength and glycerol concentration. By simultaneously reducing all three parameters while increasing the precipitant concentration, nucleation of crystals was induced but the number of nuclei kept to a minimum. Thus, 10 ml of Cry1Ac at the starting conditions (see x2.3) was dialysed at room temperature against 2 ml of 65±69 mM piperazine pH 9.8 containing 25±29 mM NaBr, 21±25%(v/v) glycerol, 9% MPD and 1% polyethyleneglycol 350 monomethyl ether. Crystals appeared in 7±10 d. After day 10 the buttons were transferred to 277 K, where crystals were more stable than at room temperature.
Since the starting Cry1Ac concentration could not be made greater than 3.5 mg ml À1 without risking uncontrolled nucleation, growth of the crystals soon stopped. Over the next 1±2 months, crystal growth was forced to continue by adjusting the reservoir composition in small increments to decrease protein solubility, while being careful not to trigger secondary nucleation. At intervals of 3±5 d, by diluting the reservoir with appropriate solutions, the MPD concentration was raised by 1±2% each time, NaBr lowered by 1±2 mM and glycerol lowered by 0.5%(v/v). The end point of these adjustments was approximately 15 mM NaBr, 15%(v/v) glycerol and 15%(v/v) MPD. Concentrations of other reservoir components were kept constant. Crystals of Cry1Ac grew as clusters of thin plates. By these reservoir manipulations, the maximum thickness of the plates was increased from about 10 to 25 mm.
Crystallization of the Cry1Ac±GalNAc complex
Crystals of the Cry1Ac±GalNAc complex were obtained only through cocrystallization, because crystals of the free toxin dissolved within 2 min of being transferred to a stablization buffer containing as little as 0.1%(w/v) GalNAc. Once Cry1Ac has been mixed with 2%(w/v) GalNAc in solution and dialysed against 1.5%(w/v) GalNAc (x2.3), its solubility is profoundly changed such that even after the Cry1Ac±GalNAc mixture has been extensively dialysed against GalNAcfree buffers, no crystals form under conditions used to crystallize the free toxin. This observation suggests that a speci®c highaf®nity complex between Cry1Ac and GalNAc has formed in solution prior to crystallization, which would be consistent with the ability of GalNAc to displace bound Cry1Ac from BBMV (Knowles et al., 1991; x3. 3) or from isolated APN receptors immobilized on the substrate for SPR analysis . Compared with the K i of 5 mM determined by SPR, the concentration of GalNAc added in solution was at least 13 times greater, so that on average well over 90% of the GalNAc sites on Cry1Ac should be occupied.
Cocrystallization was carried out by dialysing 10 ml of the concentrated Cry1Ac± GalNAc mixture (see x2.3) against 2 ml 68±70 mM piperazine pH 9.8 containing 28±30 mM NaBr, 20±22% glycerol, 9% MPD and 0.5% GalNAc. Similar results could be obtained when piperazine in the reservoir was substituted with 40 mM DAP pH 10.3 and the NaBr concentration reduced to 23±27 mM owing to the greater solubility of Cry1Ac in DAP than in piperazine. After equilibrating for 5±7 d during which no crystals appeared, nucleation was induced by lowering the glycerol concentration to 19±20% at the rate of 0.5% per 2 d by adding glycerol-free buffer to the reservoir. By day 15 crystals were visible and the dialysis button was transferred to 277 K. Further growth was forced by slowly reducing glycerol and NaBr concentrations while increasing the MPD concentration in the manner already described for crystallization of the free toxin. Crystals of the Cry1Ac± GalNAc complex also grew as clustered thin Table 2 Lattice constants and data-collection statistics.
Values in parentheses refer to the highest resolution shell.
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crystallization papers plates; however, they were thinner and more clustered than those of the free toxin. The maximum plate thickness reached was about 15 mm.
X-ray data collection
Single plates were broken from crystal clusters (Fig. 3) , stabilized in cryoprotection buffer and¯ash-frozen at 100 K. Table 2 shows the data-collection statistics. Using synchrotron radiation, diffraction was observed to a maximum resolution of 1.84 A Ê from Cry1Ac crystals and to 2.7 A Ê from Cry1Ac±GalNAc cocrystals. However, owing to radiation sensitivity and nonisomorphism among crystals of the same form (the lattice constants along the shortest axes varied by up to 2 A Ê ), the resolution of the merged data sets was limited to 2.36 A Ê for the free toxin and 2.95 A Ê for the complex. Crystals of the free toxin are triclinic; those of the complex show P2 1 symmetry. Both crystal forms contained four molecules of the 66 kDa toxin per asymmetric unit.
3.7. Non-crystallographic symmetry and molecular packing Self-rotation and self-Patterson maps of the two crystal forms are shown in Figs. 4(a) and 4(b); their molecular-packing arrangements determined by molecular replacement (Derbyshire and Li, unpublished work) are shown in Figs. 4(c) and 4(d) . For molecular replacement, the coordinates of Cry1Aa (PDB code 1ciy) were used as model for the Cry1Ac-free toxin and re®ned coordinates of Cry1Ac were then used as model for the Cry1Ac±GalNAc complex. In the P1 cell of the free toxin, the four molecules exist as a pair of pairs, one pair shown in red and yellow and the other pair in blue and green (Fig. 4c) . Within each pair, the molecules are related by a twofold rotation about a noncrystallographic axis nearly parallel to a (9 = À0.5, 3 = 90, = 180
), but contact within the pair is not extensive enough for this to be regarded as a dimer. The two pairs are related by a translation vector of fractional coordinates (0.583, 0.012, 0.516). In the P2 1 crystal of the Cry1Ac±GalNAc complex, the four molecules in the asymmetric unit are also packed as two pairs. Within each pair the two molecules (red and green or blue and yellow) are related by an approximate twofold rotation about an axis nearest to a (9 = 15.9, 3 = 99.5, = 168.1 ) and a translation vector nearest to c (À0.034, 0.162, 0.484). The red/green pair is related to the blue/yellow pair by a translation vector of fractional coordinates (0.497, 0.450, 0.0). As shown in Fig. 4(d) , the non-crystallographic symmetry operations combined with the crystallographic 2 1 screw along b gives rise to a grouping of four molecules made up by the green and yellow molecules in two adjacent asymmetric units, which has a very similar packing arrangement to the four molecules contained in the P1 lattice of the free toxin (Fig. 4c) .
Discussion
Physiological relevance of Cry1Ac aggregation
The tendency of activated Cry1Ac and other -endotoxins to aggregate is well documented. Cry1Ac was reported to aggregate in HEPES at neutral pH in a time-dependent manner . Time-dependent aggregation of several -endotoxins including Cry1Ac at neutral and alkaline pH was detected by size-exclusion chromatography (Guereca & Bravo, 1999) , which was thought to re¯ect the oligomerization anticipated in pore formation under physiological conditions. Our dynamic light-scattering data showed a heterogeneous aggregate size and a dependence of size on the buffer used (Table 1a) . Therefore, the aggregation in vitro cannot be compared directly with oligomerization Non-crystallographic symmetry (a, b) and packing arrangement (c, d) of Cry1Ac molecules in the P1 lattice of the free toxin (a, c) and the P2 1 lattice of the Cry1Ac±GalNAc complex (b, d). The four noncrystallographically related monomers within each asymmetric unit are coloured red, yellow, green and blue. In (c), the P1 cell of the toxin is viewed along the non-crystallographic twofold which is nearly parallel to a, with b pointing down and c pointing to the upper right. In (d) the view is down the crystallographic 2 1 axis along b, with a pointing to the lower right and c pointing up. Note the ordered DAP molecules bound at the conserved molecular interface in both crystal forms. under more physiological conditions (Aronson et al., 1999) .
Diaminopropane as deaggregation agent
Overcoming protein aggregation is critical to success in crystallization. We were able to obtain puri®ed monomeric Cry1Ac only by using the diamine buffer 1,3-diaminopropane (DAP) throughout protein puri®-cation. The deaggregating effect of DAP is probably a consequence of its capacity for bivalent hydrogen bonding and hydrophobic interactions. This is supported by details of DAP interaction with Cry1Ac in the structures of the free Cry1Ac and Cry1Ac± GalNAc complex (Derbyshire, Ellar & Li, unpublished work). There is a conserved molecular interface that occurs in the P1 crystals of Cry1Ac between the noncrystallographically related red and blue molecules (Fig. 4c ) and in the P2 1 crystals of the complex between two crystallographically related green molecules (Fig.  4d) . At this interface an ordered DAP molecule has been located in both structures, where its N1 atom is hydrogen bonded to the peptide carbonyl O atom of Asn418 on one protein molecule and its N3 atom is hydrogen bonded to the peptide carbonyl O atom of Asn275 and peptide N atom of Asp277 on the neighbouring molecule, while its C atoms form van der Waals contacts with several non-polar protein side chains from both protein molecules. Since the P1 crystals of the free toxin were grown in piperazine buffer rather than DAP and the same P2 1 crystals of the Cry1Ac±GalNAc complex can be grown in either DAP or piperazine buffer, the bound DAP molecule must have originated from the puri®cation and become intercalated at the protein interface when puri®ed protein was dialysed against low concentrations of the crystallization reagents MPD and glycerol. Our observa-crystallization papers tion suggests that DAP binding to selected sites on the protein surface can prevent nonspeci®c protein aggreagation and its capacity to bridge two protein molecules can catalyse formation of limited aggregates favourable to ordered crystal growth.
